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MicroRNAs (miRNAs) are small non-coding RNAs 18–25 nucleotides (nt) long able to
ﬁne-tune post-transcriptional gene expression. Extensive investigation into biogenesis,
mechanism of action and functions of miRNAs has clearly revealed their prompt control
in developmental timing, differentiation, proliferation, cell death, and metabolism. Dereg-
ulation of miRNA-mediated pathways may contribute to pathological conditions such as
tumors, including hematological cancers, thus suggesting that miRNAs act both as tumor-
suppressor genes (TSG) and oncogenes (OG). Here, we provide an overview of the current
understanding of the aberration of miRNA biogenesis, activity, and post-transcriptional
control in leukemogenesis.
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miRNA BIOGENESIS AND FUNCTION
MicroRNAs (miRNAs) are small, 18–25 nucleotide-long non-
coding RNA molecules, known to be key regulatory elements in
a wide range of biological functions. The ﬁrst to be described, in
the early 1990s, were lin-4 and let-7, regulators of developmental
timing in Caenorhabditis elegans (Lee et al., 1993;Wightman et al.,
1993), initially called small temporal RNAs (stRNAs; Pasquinelli
et al., 2000) and later renamed miRNAs (Lagos-Quintana et al.,
2001). In the last two decades a considerable, though only partial,
understanding of the ﬁne regulation operated by and modu-
lated on miRNAs has been achieved. The biogenesis of mature
miRNAs begins from transcription of primary transcripts called
pri-miRNAs by RNA polymerase II. miRNA transcription can be
related to independent miRNA-coding gene units, non-coding
RNA transcripts, and protein-coding genes. About 50% of miR-
NAs are expressed as polycistronic miRNAs in clusters under the
control of a unique promoter. Several miRNA genes show compa-
rable characteristics to protein-coding genes, such as the relative
incidence of CpG islands, TATA box, TFIIB recognition, initiator
elements, and histone modiﬁcations (Ozsolak et al., 2008; Cor-
coran et al., 2009). Primary miRNA transcripts are characterized
by a hairpin RNA structure with 7-methyl-guanylate (m7G) cap
at 5′-end, a poly(A) tail, and may include introns (Czech and
Hannon, 2011). In the nucleus, pri-miRNAs are recognized by a
microprocessor complex containing the ribonuclease Drosha, its
cofactor DiGeorge critical region 8 (DGCR8) and several other
factors such as EWSR1, FUS, numerous heterogeneous nuclear
ribonucleoproteins (hnRNPs), p68 (DDX5) and p72 (DDX17)
DEAD-box helicases (Gregory et al., 2004). The Drosha com-
plex recognizes the terminal hairpin loop (≥10 nt) and cleaves
22 nt, or 2 helix turns, from the terminal loop/stem junction
by cropping (Zeng and Cullen, 2004). The resulting shortened
hairpin structure (pre-miRNA) comprises about 70 nt with a
2 nt 3′ overhang and a phosphate group at the 5′-end (Han
et al., 2006; Seitz and Zamore, 2006). However, recent ﬁndings
have identiﬁed some miRNAs, called mirtrons, located within
intron regions of protein-coding genes, which bypass the Drosha
processing step using intronic splicing to produce pre-miRNAs
(Okamura et al., 2007; Ruby et al., 2007). pre-miRNAs are then
translocated into cytoplasm by exportin 5 (Exp-5) in coopera-
tion with Ran-GTP61 (RAS-related nuclear protein with bound
GTP). Exp-5 speciﬁcally interacts with double-stranded RNAs of
least 16 bp facilitated by 3′ overhang and, after GTP hydroly-
sis, releases pre-miRNAs (Bohnsack et al., 2004; Zeng and Cullen,
2004). In cytoplasm, processed miRNA precursors are cleaved
by another type-2 RNase III enzyme, Dicer, to produce ∼22
nt duplex miRNAs with 3′ overhang (Kim et al., 2009). From
the resulting miRNA duplex, the mature miRNA guide strand
is loaded onto Ago (Argonaute)-2 protein with Dicer and TRBP
(HIV transactivating response RNA-binding protein), forming
the so-called miRNA-induced silencing complex (miRISC), while
the passenger strand is usually degraded (Bartel, 2009) or, in
some cases, can become functional miRNA (Kuchenbauer et al.,
2011). miRNA-modulated gene regulation results in a complex
post-transcriptional mechanism mediated by the complementar-
ity between the “seed” sequence (positions 2–8 from the 5′-end
of the miRNA) and the “seed-match” sequence (generally in the
3′UTR of the target mRNA). The inhibitory function of miRNAs
can occur either via translational repression or mRNA degrada-
tion, depending on the lesser or greater degree of miRNA/mRNA
complementarity respectively (Filipowicz et al., 2008). Moreover,
miRNAs may target DNA or hnRNPs, or increase expression of a
target mRNA (Garzon et al., 2010). To date, approximately 1800
human miRNAs have been identiﬁed (http://www.mirbase.org/)
and over one third of human genes are putative miRNA targets
(Croce, 2009).
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miRNAs AS ACTORS IN NORMAL HEMATOPOIESIS
Strongly conserved among distantly related organisms, miRNAs
are involved in a variety of biological processes including cell cycle
regulation, apoptosis, differentiation, development, metabolism,
and aging (Lujambio and Lowe, 2012). Hence, deregulation of
miRNA networks seems to contribute to malignant transforma-
tion. The causes of altered miRNA expression and/or function are
disparate and include deletion, ampliﬁcation,mutation, transcrip-
tional deregulation, and epigenetic changes, which may involve
miRNAs directly or their regulatory factors (Ryan et al., 2010;
Figure 1).
Recent studies have emphasized the ﬁne-tuning of gene expres-
sion by several miRNAs in the hematopoietic system and the clear
relationship between imbalance of miRNA proﬁles and leukemic
phenotype (O’Connell et al., 2010a). In the hematopoietic sys-
tem, a wide set of highly specialized cells are produced from a
common stem cell population by a hierarchical differentiation
process. miRNAs have been shown to be key supporting actors
in molecular control networks of hematopoiesis, including lin-
eage decisions, stem cell progenitor transitions, niche control and
other cell functions (O’Connell et al., 2010b; O’Connell and Bal-
timore, 2012). To highlight their importance in hematopoiesis, in
vivo studies in conditional knockout mice were performed, given
that Dicer knockouts are embryonic lethal (Bernstein et al., 2003).
Likewise, DGCR8-deﬁcient embryonic stem (ES) cells are blocked
in G1 phase and exhibit defective differentiation (Wang et al.,
2007, 2008). Furthermore, Ago2 inactivation causes signiﬁcant
hematopoietic defects (O’Carroll et al., 2007).
Several miRNAs play a critical role in stem/progenitor, lym-
phoid, myeloid, erythroid, and megakaryocytic biology, and in
the immune function of these cell lineages (O’Connell et al.,
2010b). Individual miRNAs are essential in the maintenance, dif-
ferentiation, and control of lineage determination of ES cells.
miRs-290–295, miR-296, miR-21, and miR-22 are increased fol-
lowing induction of differentiation (Gangaraju and Lin, 2009;
Wang et al.,2009). ThekeyES cell transcription factors,Oct4, Sox2,
Nanog, and Tcf3, are associated with miRNA promoters preferen-
tially expressed in ES cells, such as miR-290 cluster (Marson et al.,
2008). miR-134, miR-296, and miR-470 up-regulated on retinoic
acid (RA)-induced differentiation, target Nanog, Oct4, and Sox2,
leading to transcriptional and morphological changes character-
istic of differentiating mouse ES cells (Tay et al., 2008). miR-196b
is most abundantly expressed in short-term hematopoietic stem
cells (HSC), but is downmodulated in progenitors (Popovic et al.,
2009). Moreover, miR-150 is involved in cell fate decisions by
tuning MYB levels in mixed erythroid/megakaryocytic progeni-
tors (EMP); high miR-150 expression triggers megakaryoid (Mk)
differentiation, while lowmiR-150 expression favors erythroid dif-
ferentiation (Lu et al., 2008). miR-10a, miR-10b, miR-17, miR-20,
miR-106, and miR-126 are down-regulated during Mk differ-
entiation. Interestingly, the regulatory circuitry of miR-223 is
implicated in myelopoiesis: nuclear factor I-A (NFI-A) maintains
miR-223 at low levels, whereas after RA-induced differentiation
C/EBP alpha up-regulates miR-223 expression, both acting via
CCAAT-box binding on miR-223 promoter (Fazi et al., 2005).
Increase of miR-27 expression is required to downmodulate





























FIGURE 1 | Mechanism of miRNA expression and/or function
perturbation. (1) Epigenetic changes (DNA methylation and histones
modiﬁcations); Transcription factor or regulatory gene alteration.
(2) Genomic changes (deletions, ampliﬁcations, translocation, SNPs,
mutations). (3) Functional or expressional biogenesis pathway alterations
(Drosha down-regulation; XPO5 mutation; DISC assembly defects).
(4) Alteration of target mRNAs 3′UTR.
2009). In the Mk lineage, miR-28 has been shown to inhibit
differentiation by targeting thrombopoietin receptor (TpoR;
Girardot et al., 2010). AML1 itself controls monocytopoiesis in
a mutual negative feedback loop with miRNA 17-5p-20a-106a:
AML1 binds the miRNA 17-5p-92 and 106a-92 cluster promoters
and transcriptionally inhibits their expression; miRNA 17-5p-
20a-106a suppresses AML1 protein expression, leading to blast
proliferation and inhibition of monocyte differentiation andmat-
uration (Fontana et al., 2007). miR-125b supports myelopoiesis,
but not G-CSF-induced granulocytic differentiation, by regulat-
ing c-Jun and JunD pathways (Surdziel et al., 2011). For erythroid
differentiation of CD34+ cells, miR-221 and miR-222 are down-
modulated and unblock kit protein production at mRNA level
(Felli et al., 2005). Expression of miR-451 is signiﬁcantly up-
regulated during erythroid maturation (Zhan et al., 2007). In
normal human CD34+ cells, miR-15a and miR-16-1 can repress
c-Myb expression with a negative autoregulatory feedback loop
between c-Myb and the miR-15a/miR-16-1 cluster (Zhao et al.,
2009). miR-144/451 cluster is controlled by transcription fac-
tor GATA-1, a master regulator of erythroid cell development
(Orkin and Zon, 2008). miR-24 has been shown to down-regulate
erythropoiesis by targeting hALK4, reducing activin-mediated
Smad2 phosphorylation and attenuating transcriptional responses
of activin (Wang et al., 2008). Convincing evidence has demon-
strated that severe impairment of miRNA regulatory mechanisms
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affect immune development/response leading to immune dis-
orders (Ha, 2011). miRNA functions are essential to maintain
immune homeostasis. For example, overexpression of miR-34a
leads to disruptions in B-cell development by repressing Foxp1
(Rao et al., 2010). Knockout of miR-155 affects T-cell differentia-
tion, germinal center B-cell responses, and responses to bacterial
and viral infection (O’Connell et al., 2007; Rodriguez et al., 2007;
Thai et al., 2007). miR-146a plays a key role in innate immunity,
inﬂammatory response, and viral infection. Both TLR activa-
tion and inﬂammatory stimulation can lead to up-regulation
of miR-146a, which in turn negatively regulates innate immu-
nity by repressing its targets, such as IRAK1, IRAK2, TRAF6,
and TBP (Taganov et al., 2006; Hou et al., 2009; Sinha et al.,
2010). By inhibiting miR-155 expression progesterone can down-
regulate both MyD88 and TRIF-dependent signaling pathways as
well as IL-6 and IFN-β production (Sun et al., 2012b). Recent
studies reported that miR-23b induces tolerogenic dendritic cell
(DC) activity and Treg responses in vitro through inhibition of
the Notch1 and NF-κB signaling pathways (Zheng et al., 2012).
miR-155-deﬁcient myeloid DCs have an impaired ability to trig-
ger T-cell activation after antigen presentation (Rodriguez et al.,
2007). In the lymphocyte lineage, the mir-17-92 cluster is highly
expressed in B- andT-precursor cells and its expression diminishes
aftermaturation. The loss of miR-17/miR-19b causes protein-level
changes of TGF-βRII, CREB1 and Pten and affects thymus selec-
tion of the nTreg population (Jiang et al., 2011). Finally, miR-125b
is able to activate immune responses of macrophages by reducing
IRF4 levels (Chaudhuri et al., 2011). Taken together, these ﬁndings
underscore the fundamental role of miRNAs in the synergic reg-
ulation of pathways, such as cell fate decisions, development and
differentiation of hematopoietic and immune cells.
CRUCIAL ROLE OF miRNAs IN LEUKEMOGENESIS
Leukemogenesis is a complexprocess that involvesmultiple genetic
and epigenetic events. It underlies a group of clonal malignan-
cies of blood and bone marrow characterized by the presence
of chromosomal abnormalities, such as deletions, transloca-
tions or inversions, or genetic mutations affecting the control of
hematopoietic cell proliferation and differentiation. Leukemia is
classiﬁed both clinically and pathologically as acute or chronic
(based on differentiation state and clinical evidence) and myeloid
or lymphoid (according to cell type). Extensive deregulation of
miRNA has been observed in leukemia, and many studies sup-
port its role in aberrant signaling pathways identiﬁed in chronic
lymphocytic leukemia (CLL), chronic myeloid leukemia (CML),
acute lymphoblastic leukemia (ALL), and acute myeloid leukemia
(AML).
Chronic lymphocytic leukemia is the most common leukemia
in theWestern world and is fairly heterogeneous. It can be charac-
terized by IgVH gene mutations, CD38 and ZAP-70 expression,
presence of chromosomal abnormalities and p53 dysfunction,
causing gradual accumulation of functionally immature B-cells,
arrested at G0 or G1 phase (Dohner et al., 2000; Pettitt et al., 2001;
Rosenwald et al., 2001; Wiestner et al., 2003; Damle et al., 2007).
miRNA variations impact on malignant CLL cells triggering eva-
sion of apoptosis, proliferation, and stimulation of angiogenesis
and invasion. Bullrich et al. (2001) and Calin et al. (2002) ﬁrst
reported the involvement of miRNAs in human cancer, identi-
fying a precise region on chromosome 13q14 that contains two
miRNA genes, miR-15a and miR-16-1, deleted or down-regulated
in about 69% of CLL patients. Via a feedback circuitry, these
two miRNAs directly down-regulate tumor suppressor protein
TP53, miR-34a, miR-34b, and miR-34c, and increase protein
levels of ZAP70 (Fabbri et al., 2011). In CLL patients with 13q
deletions, this mechanism is altered with a consequent reduc-
tion of CDKN1A, BBC3, and BCL2 expression (Cimmino et al.,
2005; Fabbri et al., 2011). Moreover, miRNA expression proﬁles
characterizing CLL phenotype have demonstrated that down-
regulation of miR-223, miR-29c, miR-29b, and miR-181 families
is strongly associated with disease progression in CLL cases har-
boring 17p deletion (Visone et al., 2009), while miR-21, miR- 92,
miR-101, miR-150, miR-155, miR-146a, and miR-17-92 fami-
lies are all highly expressed in B-CLL (Calin et al., 2004, 2005;
Fulci et al., 2007). In particular, miR-155 and miR-21 are signif-
icantly higher in NK cell than in B-cell lymphomas/leukemias,
and down-regulate PTEN, PDCD4, or SHIP1 with up-regulation
of phosphorylated AKT (ser473; Yamanaka et al., 2009). NFκB,
AP1, and MYB transcription factors themselves regulate miR-155
(Vargova et al., 2011).
A further indication of the importance of miRNAs in CLL
pathogenesis is given by miR-29 and miR-181 in regulating T-
cell leukemia/lymphoma 1 (TCL1) oncogene, overexpressed in
25–35% of CLL patients (Pekarsky et al., 2006). They are down-
regulated in cases with 11q/17p deletion and in aggressive CLLs
correlating with poor prognosis. In particular, miR-29 family is
known to target CDC42, which reduces p53 levels and PI3K activ-
ity (Park et al., 2009). miR-181 inhibits BCL-2, MCL-1, and XIAP
protein by direct binding to 3′UTR (Zhu et al., 2012). Finally, low
expression of miR-34a has been associated with both 17p deletion
and chemotherapy resistance in CLLs (Dijkstra et al., 2009; Zenz
et al., 2009).
Chronic myeloid leukemia is a disorder marked by an increase
in myeloid, erythroid cells, and platelets in peripheral blood with
severemyeloid hyperplasia in bonemarrow and a translocation on
chromosome 9 and 22 (the so-called Philadelphia chromosome)
in>95% of CML patients (Croce, 2008). miRNA expression pro-
ﬁles inmononuclear andCD34+ cells fromCMLpatients revealed
that miR-10a, miR-150, and miR-151 are downmodulated and
miR-96 is up-regulated compared with healthy controls (Agirre
et al., 2008). Moreover, miR-17-92 are overexpressed for transacti-
vation induced by both breakpoint cluster region-c-abl oncogene
(BCR/ABL) and c-Myc in primary CML CD34+ cells in chronic
phase compared with normal CD34+ cells (Venturini et al., 2007),
and are regulated by members of the E2 transcription factor fam-
ily in a negative feedback loop (O’Donnell et al., 2005). (Bueno
et al. (2008) found that miR-203 functions as a tumor suppressor
and is silenced by hypermethylation in hematopoietic malignan-
cies expressing either ABL1 or BCR/ABL1. Chaubey et al. (2009)
detected that miR-219-2 and miR-199b can be hemizygously lost
in a signiﬁcant proportion of CML cases with der (9q) deletion. As
tumor suppressor, miR-181a targets RalA associated with cell pro-
liferation, G2-phase arrest, and apoptosis in CML (Fei et al., 2012).
Eiring et al. (2010) demonstrated aRISC-independent decoy activ-
ity for miR-328, which is down-regulated in CML blast crisis
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(CML-BC). Loss of miR-328 occurs in CML-BC in a BCR/ABL
dose- and kinase-dependent manner through the MAPK-hnRNP
E2 pathway. Restoration of miR-328 expression rescues differen-
tiation and impairs survival of leukemic blasts by simultaneously
interacting with the translational regulator poly(rC)-binding pro-
tein hnRNP E2 and with mRNA encoding survival factor PIM1,
respectively. Interaction with hnRNP E2 is independent of the
miRNA seed sequence and leads to release of CEBPA mRNA by
hnRNP E2-mediated translational inhibition.
Acute lymphoblastic leukemia is one of the most common
malignancies observed in the pediatric age group. It is char-
acterized by clonal proliferation of early B- and T-lymphocyte
progenitors and results in the accumulation of leukemic lym-
phoblast in bone marrow and various extra-medullary sites
(Crazzolara and Bendall, 2009). Danen-van Oorschot et al. (2012)
showed that 14 miRNA genes are up-regulated (miR-128a, miR-
142-3p, miR-142-5p, miR-150, miR-181a, miR-181b, miR-181c,
miR-193a, miR-196b, miR-30e-5p, miR-34b, miR-365, miR-582,
miR-708) and ﬁve are down-regulated (miR-100, miR-125b, miR-
151-5p, miR-99a, let-7e) in ALL cells compared with normal
CD34+ cells. Speciﬁc miRNA expression proﬁles have been
deﬁned in major subtypes of ALL (T-cell, MLL-rearranged, TEL–
AML1-positive, E2A-PBX1-positive, and hyper-diploid acute lym-
phoblastic leukemia) and identiﬁed as highly predictive of clinical
outcome (Schotte et al., 2011). Recently,Mi et al. (2007) identiﬁed
27 miRNAs that were differentially expressed in ALL compared
with AML; among these, miR-128a and miR-128b were signiﬁ-
cantly overexpressed, whereas let-7b and miR-223 were strongly
down-regulated. miR-128b (higher in ALL vs AML) was also
overexpressed in ALL vs normal CD19+ cells. Overexpression
of miR-128 in ALL was at least partly associated with promoter
hypomethylation and not with an ampliﬁcation of its genomic
locus.
Acute myeloid leukemia is characterized by an accumulation of
granulocytic ormonocyte precursors in bonemarrow and periph-
eral blood. miRNA patterns have been correlated with cytogenetic
and molecular subtypes of AML (Jongen-Lavrencic et al., 2008; Li
et al., 2008; Saumet et al., 2009). miRNA expression has also been
investigated in some AMLs associated with rare translocations.
Interestingly, an elevated expression of miR-125b-1 was observed
in AMLs carrying the t(2;11)(p21;q23) translocation (Bousquet
et al., 2008). Similarly, miR-125b overexpression causes highly
invasive myeloid leukemia, such as BCR/ABL-positive leukemia,
and has been associated with drug resistance in TEL–AML1-
positive pediatric ALL (Gefen et al., 2010; Schotte et al., 2011). Its
leukemogenesis pathway may include down-regulation of IRF4,
a transcription factor that inhibits proto-oncogene BCL-6 (B-cell
CLL/lymphoma6) in lymphoma (Saito et al., 2007; Bousquet et al.,
2010). Studies have identiﬁed other miRNAs whose expression is
altered in acute promyelocytic leukemia (APL). Particularly, miR-
342 is downmodulated by the binding of PML/RAR-alpha to its
promoter in leukemic compared to normal promyelocytes (Carec-
cia et al., 2009) and is up-regulated during APL differentiation
upon ATRA treatment (De Marchis et al., 2009).
A recent study provided evidence that some miRNAs are
involved in control of DNA methylation machinery, and their
deregulation may be partly responsible for aberrant DNA
hypermethylation observed in AMLs. Particularly, miR-29b over-
expression inAMLcells results in amarked reduction in expression
of DNAmethyltransferases DNMT1,DNMT3A, and 3B leading to
a decrease in global DNA methylation and re-expression of genes
silenced through hypermethylation. In addition, miR-29b indi-
rectly down-regulates DNMT1 by targeting Sp1 (Garzon et al.,
2009). Moreover, DNA methylation analyses of the CpG island
of C/EBPα identiﬁed a densely methylated upstream promoter
region in 51% of AML patients and the silencing of miR-124a by
epigenetic mechanisms. This miRNA targets the C/EBPA 3′UTR
(Hackanson et al., 2008). Another study showed that miR-29b
is involved in a protein–miRNA network including SP1, NFκB,
and HDAC, whose deregulation results in KIT overexpression in
AML and is associated with adverse clinical outcome (Liu et al.,
2010). Fazi et al. (2005) also showed that AML1/ETO oncopro-
tein triggers heterochromatic silencing of miR-223 transcription
by recruiting chromatin-remodeling enzymes (HDAC, DNMT
and MECP2) at an AML1-binding site on the pre-miR-223 gene,
thus contributing to the differentiation block of AML1/ETO+
myeloid precursors. In myeloid progenitor cells and AML patients
with t(8;21), Zaidi et al. (2009) reported that Runx1 and AML1-
ETO occupy the miR-24-23-27 locus and reciprocally control
miR-24 transcription, enhance growth factor-independent pro-
liferation and block granulocytic differentiation of myeloid cells.
Down-regulation of miR-34b caused by promoter methylation
has also been explored in AMLs as a possible determinant of
an increase in its target cyclic AMP-response element binding
(CREB; Pigazzi et al., 2009). In addition, miR-212 has been
reported as an independent prognostic factor associated with pro-
longed overall survival and relapse-free survival (Sun et al., 2012a).
Finally, particular emphasis should be focused on the develop-
ment of next-generation deep-sequencing data for novel miRNAs
and both somatic and germline genetic variants of leukemia
subtype-speciﬁc miRNA gene identiﬁcation (Calin et al., 2005;
Starczynowski et al., 2011). This technique has also applied to
accurately measure mature miRNA expression and deﬁne their
functional role in miRNA stability and processing (Ramsingh
et al., 2010). Recent ﬁndings showed several novelmiRNAs located
in leukemia-associated genomic alterations. For example, miR-
145 and miR-146a are commonly found in deleted region in
del (5q) myeloid malignancies and are down-regulated in cell
lines with the chromosome 5q deletion or diploid at this locus
compared with CD34 cells. Notably, miR-481, located within
a deleted region on chromosome 7q, is able to target menin-
gioma 1 (Mn1). Its higher expression is a predictive factor of
poor outcome in patients with AML (Starczynowski et al., 2011).
Similarly,miR-223* completesmiR-223 function, activating apop-
tosis and/or inhibiting self-renewal or proliferation of progenitor
cells. High expression levels have been associated with a better
overall survival rate in AML patients with normal cytogenetics
(Kuchenbauer et al., 2011).
CONCLUSION
Control of gene expression by miRNAs is a ﬁnely regulated
and complex process able to determine cellular phenotype and
fate. Distinctive miRNA expression proﬁles emerging from the
current literature indicate that these patterns might prove useful
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for the classiﬁcation of aberrant phenotypes. miRNA alterations
seem to actively and profoundly contribute to malignant trans-
formation and progression of cancers, including leukemia. Based
on distinctive miRNA signatures in different leukemia networks,
miRNAs are proposed as potential biomarkers with consider-
able impact in diagnosis and prognosis, as well as in detecting
cancer at its earliest stages, characterizing speciﬁc cancers or
deﬁning “patient clusters” evasive or responsive to treatment.
In addition, selective modulation of target genes involved in
leukemogenesis by miRNA has supported the development of
miRNA-based therapeutic strategies. Depending onmiRNA func-
tion and its status in cancer tissues, new therapeutic approaches
have been generated to restore a loss of miRNA function or to
inhibit it. In both cases, the reprogramming of miRNA leads
to a re-establishment of non-pathological pathways. To date,
some miRNA antagonist/mimic-based oncology therapies using
modiﬁed oligonucleotides and effective delivery systems, such as
adeno-associated virus (AAV), cationic liposomes or polymer-
based nanoparticles, have been validated in clinically relevant
animal models and are currently in pre-clinical development. The
systemic delivery of miR-155 antisense encapsulated in polymer
nanoparticles (Babar et al., 2012) and miR-34 mimics in ioniz-
able liposome (Bader, 2012) to pre-B-cell tumors in vivo seems
very promising. The latter is the ﬁrst miRNA mimic due to enter
phase I clinical trials in early 2013 for leukemias and lymphomas
(Mirna Therapeutics Inc, 2011). Current advances conﬁrm the
potential clinical miRNA-based applications in effective, tolerated
and “custom” hematological cancer treatment.
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